Navigation Links
GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab)
Date:5/16/2008

revention, supportive care, chemotherapy and targeted therapies. For more information about GSK Oncology, visit http://www.gskoncology.com.

About GlaxoSmithKline

GlaxoSmithKline -- one of the world's leading research-based pharmaceutical and healthcare companies -- is committed to improving the quality of human life by enabling people to do more, feel better, and live longer. To access the latest GSK Oncology media materials, visit http://www.gsk.com/media. For more information about GSK Oncology, visit http://www.gskoncology.com.

TYKERB Important Safety Information

TYKERB has been associated with hepatotoxicity. The hepatotoxicity may be severe and deaths have been reported. Causality is uncertain. Patients should receive liver function tests before initiation of treatment, every 4 to 6 weeks during treatment, and as clinically indicated. A dose reduction in patients with severe pre-existing hepatic impairment should be considered. Discontinue and do not restart TYKERB if patients experience severe changes in liver function tests.

As with other therapies for HER2 overexpression, TYKERB has been associated with reports of decreases in left ventricular ejection fraction (LVEF). Caution should be taken if TYKERB is to be administered to patients with pre-existing cardiac conditions, including uncontrolled or symptomatic angina, arrhythmias, or congestive heart failure. LVEF should be evaluated in all patients prior to and during treatment with TYKERB.

Diarrhea was the most common adverse event resulting in discontinuation of study medication. Proactive management of diarrhea with anti-diarrheal agents is important, and severe cases of diarrhea may require administration of oral or intravenous electrolytes and fluids and interruption or discontinuation of therapy with
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
2. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
3. BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting
4. IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program
5. Biopure Announces Publication of Phase II Proof-of-Concept Coronary Trial
6. Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization
7. Kosan Announces Data Presentations at ASCO 2008 Annual Meeting
8. XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting
9. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
10. Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury
11. Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...TAINVIEW,Calif.,Nov.24/PRNewswire/--SatelliteHealt...dneydialysisservicesandamajorsponsorofnephrologyre...urvivorandchefEliasNasrallahinhisefforttosupportth...asNasrallahbuiltasuccessfulcareerasachefforthepast...yearsago,whenhewasdiagnosedwithEndStageRenalDiseas...
(Date:11/24/2009)...ORK,Nov.24/PRNewswire/--AFOXThanksgivingDaytelevis...entisU.S.remindsviewersthattheholidaysareatimetobe...randforallthosewhofightthatbattleeachdayassurvivor...aturethehistoricreturntotheiceofcancersurvivorsSco...iaNewton-JohnandDavidFosterwhowillperform"HopeisAl...
(Date:11/23/2009)...INGTON,Nov.23/PRNewswire-USNewswire/--FebeDurango-...2009,toparticipatinginaschemetodefraudtheExport-Im...llion,announcedAssistantAttorneyGeneraloftheCrimin...valdoL.GratacosoftheEx-ImBank,OfficeoftheInspector...ardW.RobertsinU.S.DistrictCourtinWashingtontoaone-...
Breaking Medicine Technology:Satellite Healthcare and Renal Disease Survivor Elias Nasrallah Join Forces to Support the Homeless This Holiday Season 2FOX Thanksgiving Day Special 'Kaleidoscope' Unites Cancer Survivors on Ice and in Song to Celebrate Survivorship 2FOX Thanksgiving Day Special 'Kaleidoscope' Unites Cancer Survivors on Ice and in Song to Celebrate Survivorship 3Colombian National Pleads Guilty to Role in Defrauding the Export-Import Bank of the United States of More Than $1 Million 2Amgen to Present at the Morgan Stanley Global Healthcare Unplugged Conference 14004 1Amgen to Present at the Morgan Stanley Global Healthcare Unplugged Conference 14004 2Phase 3 Trial of Aflibercept in Metastatic Pancreatic Cancer Discontinued 4975 1Phase 3 Trial of Aflibercept in Metastatic Pancreatic Cancer Discontinued 4975 2Phase 3 Trial of Aflibercept in Metastatic Pancreatic Cancer Discontinued 4975 3Phase 3 Trial of Aflibercept in Metastatic Pancreatic Cancer Discontinued 4975 4Phase 3 Trial of Aflibercept in Metastatic Pancreatic Cancer Discontinued 4975 5HPV Vaccine Study Shows Why Few Women Getting Shots 56961 1HPV Vaccine Study Shows Why Few Women Getting Shots 56961 2
... Headache specialists meet,today in Boston for the...ety. Learn more about headache and face pain devel...five advances in headaches -- and what,researchers...tion, contact: Gina Czark at 312.558.1770, ext.,13...chenews.org ., Among the topics being presented, ...
...patent covering the anti-HCV drug PSI-6130 and its... PRINCETON, N.J., June 26 Pharmasset, Inc.,(Nasda... and Trademark Office,has issued a Notice of Allow...titled, "Modified Fluorinated Nucleoside Analogues...of molecules invented at Pharmasset,for the treatm...
Other Medicine Technology:Headache Specialists Convene in Boston For 50th Annual American Headache Society Meeting 2Pharmasset Receives Notice of Allowance 2Pharmasset Receives Notice of Allowance 3Pharmasset Receives Notice of Allowance 4
(Date:11/24/2009)... , A recent study shows that 95 percent of radiat...ch as positron emission tomography (FDG-PET), magn...mputed tomography (4DCT) for target delineation (t...ing cancer), according to an article in the Decemb...f Radiology , ( JACR , www.jacr.org ). , In def...
(Date:11/24/2009)... , Researchers at the University of Miami School ...ients who underwent liver transplants for nonalcoh... disease (ETOH) and found no statistically signifi... between the NASH and ETOH groups. Study findings ...splantation , a journal published by Wiley-Blackwe...
(Date:11/24/2009)... , (Boston) Researchers from Boston University S... Biomedical Engineering Department have identified... to distinguish between cancer and normal cells wi... researchers have developed a new computational st...ify key biological pathways (molecular circuits) t...
(Date:11/24/2009)... ,, SILVERSPRING,Md.,Nov.24/PRNewswire-USNew...erefoodisservedareallpartoftheholidaycheer.Butthem.... ,, (Logo: http://www.newscom.com/cgi-bin/prnh...neillnessarevomiting,diarrhea,andflu-likesymptoms,...tedfoodordrinksareconsumed. ,, "Thegoodnewsisth...
(Date:11/24/2009)... ,, NEWYORK,Nov.24/PRNewswire/-- Asyear-end...esthatcansavetaxesthisyearandnext.Tohelpyoutakeadv...mE.Massey,SeniorTaxAnalystatThomsonReuters,highlig...remployees: ,, Healthflexiblespendingaccounts...nualopportunitytosavetaxesbyplacingfundsintheiremp...
Breaking Medicine News(10 mins):Health News:New data emerges on liver transplant survival rates 2Health News:New data emerges on liver transplant survival rates 3Health News:Researchers identify proteins in lung cancer cells that may provide potential drug targets 2Health News:FDA Consumer Health Information: Food Safety Tips for Healthy Holidays 2Health News:The Right Tax Moves for Employees to Make Before Year-End 2Health News:The Right Tax Moves for Employees to Make Before Year-End 3
....,(NasdaqGS: VARI) today announced that its Board ...o $100 million in shares of its common stock. The ... 31, 2009., "This share repurchase program is ano... Vice President, Chief,Financial Officer and Treas...
...as no better than placebo, study finds , ,...drug oxcarbazepine (Trileptal) does not seem to pr...s. , Migraines affect more than 28 million America...would also work against migraines. , However, "the...
...es,viewed as a normal part of aging. It shouldn,t ...hood of disability, placement in a nursing,home, a...ite men over age,85 have the highest suicide rate ...take them for symptoms of another,medical disorder...
...ey-Blackwell, the scientific, technical, medical, ...Sons, Inc. (NYSE: JWa), (NYSE: JWb), today announc... the 2007 Best New Journal-Social Sciences & Human...more than 30 disciplines in order to recognize pub...
...ld Spa is pleased,to announce the appointment of f...rainer and B.S., Exercise Science., "Jeanine brin...program," said owner, Joan Wolff. "Her education a...s to take home with,them for continued improvement...
...s the day that we,celebrate love approaches, many ...tend with an emotional issue. How do you sustain a...ows who you are? Memory care,experts say the key l...ng things that make him or her happy," said Carole...
Other Medicine News:Health News:Varian, Inc. Board Authorizes New $100 Million Stock Repurchase Program 2Health News:Epilepsy Drug Doesn't Prevent Migraines 2Health News:Depression in the Elderly is Complicated but Treatable, From the Harvard Mental Health Letter 2Health News:Mind, Brain, and Education is recognized as best new journal 2Health News:Deerfield Spa Appoints New Fitness Director 2Health News:Loving the Memory-Impaired: A New Perspective on Valentine's Day 2
...national reference laboratory and a worldwide lead...nt. ARUP offers an extensive test menu of highly c...atomic pathology. Owned by the University of Utah,... of the nation's university teaching hospitals and...
...national reference laboratory and a worldwide lead...nt. ARUP offers an extensive test menu of highly c...atomic pathology. Owned by the University of Utah,... of the nation's university teaching hospitals and...
...national reference laboratory and a worldwide lead...nt. ARUP offers an extensive test menu of highly c...atomic pathology. Owned by the University of Utah,... of the nation's university teaching hospitals and...
...national reference laboratory and a worldwide lead...nt. ARUP offers an extensive test menu of highly c...atomic pathology. Owned by the University of Utah,... of the nation's university teaching hospitals and...
Medicine Products: